Page 321 - Read Online

Cervantes-Gracia et al. Vessel Plus 2020;4:27 I http://dx.doi.org/10.20517/2574-1209.2020.22 Page 19 of 19

nephropathy. Am J Kidney Dis 2006;47:439-44.
160. Baramova EN, Bajou K, Remacle A, L’hoir C, Krell HW, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and
in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-62.
161. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free
Radic Biol Med 1997;22:985-8.
162. Yu LR, Sun J, Daniels JR, Cao Z, Schnackenberg L, et al. Aptamer-based proteomics identifies mortality-associated serum biomarkers in
dialysis-dependent AKI patients. Kidney Int Reports 2018;3:1202-13.
163. Roelofs JJTH, Rouschop KMA, Leemans JC, Claessen N, de Boer AM, et al. Tissue-type plasminogen activator modulates inflammatory
responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006;17:131-40.
164. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal
transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006;281:2120-7.
165. Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked
kinase. J Am Soc Nephrol 2012;23:1329-38.
166. Lin L, Jin Y, Mars WM, Reeves WB, Hu K. Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through
FAK, Rac1, and NF-κB pathways. Am J Pathol 2014;184:2757-67.
167. Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB, et al. Regional localization of the interferon- β2 B-cell stimulatory
factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics 1988;2:203-8.
168. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced
nephropathy after coronary angiography. Nephron - Clin Pract 2008;108:c176-81.
169. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am
Soc Nephrol 2008;19):1106-15.
170. Chen J, Hartono JR, John R, Bennett M, Zhou XJ, et al. Early interleukin 6 production by leukocytes during ischemic acute kidney injury
is regulated by TLR4. Kidney Int 2011;80:504-15.
171. Alladina JW, Levy SD, Hibbert KA, Januzzi JL, Harris RS, et al. Plasma concentrations of soluble suppression of tumorigenicity-2 and
interleukin-6 are predictive of successful liberation from mechanical ventilation in patients with the acute respiratory distress syndrome.
Crit Care Med 2016;44:1735-43.
172. Nogare AL, Dalpiaz T, Veronese FJ, Gonçalves LF, Manfro RC. Noninvasive analyses of kidney injury molecule-1 messenger RNA in
kidney transplant recipients with graft dysfunction. Transplant Proc 2012;44:2297-9.
173. Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum creatinine? Transl Res 2012;159:277-89.
174. Soto K, Coelho S, Rodrigues B, Martins H, Frade F, et al. Cystatin C as a marker of acute kidney injury in the emergency department.
Clin J Am Soc Nephrol 2010;5:1745-54.
175. Marenzi G. Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score? Nat
Clin Pract Cardiovasc Med 2005;2:80-1.
176. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. Am J Roentgenol 1998;171:933-9.